Updating results

Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults (IPG634)

Evidence-based recommendations on transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia (difficulty swallowing) in adults

Interventional procedures guidance Published December 2018

Vandetanib for treating medullary thyroid cancer (TA550)

Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults

Technology appraisal guidance Published December 2018

Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)

NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence

Technology appraisal guidance Published December 2018

Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)

NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published December 2018

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults

Technology appraisal guidance Published November 2018

Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions (IPG633)

Evidence-based recommendations on percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk PCIs

Interventional procedures guidance Published November 2018

Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain (IPG632)

Evidence-based recommendations on transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain in adults

Interventional procedures guidance Published November 2018

Padeliporfin for untreated localised prostate cancer (TA546)

Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults

Technology appraisal guidance Published November 2018

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over

Technology appraisal guidance Published November 2018

Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis (IPG631)

Evidence-based recommendations on subcutaneous automated low-flow pump implantation for refractory ascites caused by liver cirrhosis in adults

Interventional procedures guidance Published November 2018

Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (IPG630)

Evidence-based recommendations on selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma in adults

Interventional procedures guidance Published October 2018

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated October 2018

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

Technology appraisal guidance Published July 2013 Last updated October 2018

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults

Technology appraisal guidance Published October 2018

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people

Highly specialised technologies guidance Published October 2018

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published October 2018

Cabozantinib for untreated advanced renal cell carcinoma (TA542)

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults

Technology appraisal guidance Published October 2018

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)

Technology appraisal guidance Published September 2018

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG629)

Evidence-based recommendations on transurethral water jet ablation for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)

Interventional procedures guidance Published September 2018

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)

Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer

Interventional procedures guidance Published September 2018

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults

Technology appraisal guidance Published September 2018

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

Technology appraisal guidance Published August 2018

Superior rectal artery embolisation for haemorrhoids (IPG627)

Evidence-based recommendations on superior rectal artery embolisation for haemorrhoids in adults

Interventional procedures guidance Published August 2018

Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)

Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias (an inserted device to help the heart beat at a normal rate)

Interventional procedures guidance Published August 2018

Sutureless aortic valve replacement for aortic stenosis (IPG624)

Evidence-based recommendations on sutureless aortic valve replacement for aortic stenosis in adults

Interventional procedures guidance Published August 2018

Dinutuximab beta for treating neuroblastoma (TA538)

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over

Technology appraisal guidance Published August 2018

Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG625)

Evidence-based recommendations on transurethral water vapour ablation for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)

Interventional procedures guidance Published August 2018

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published August 2018

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published August 2018

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine

Technology appraisal guidance Published August 2018

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (IPG623)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of delayed-union and non-union fractures

Interventional procedures guidance Published July 2018

Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing (IPG622)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of fresh fractures at high risk of non-healing

Interventional procedures guidance Published July 2018

Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (IPG621)

Evidence-based recommendations on low-intensity pulsed ultrasound (LIPUS) to promote healing of fresh fractures at low risk of non-healing in adults

Interventional procedures guidance Published July 2018

Transaxial interbody lumbosacral fusion for severe chronic low back pain (IPG620)

Evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults

Interventional procedures guidance Published July 2018

Superior capsular augmentation for massive rotator cuff tears (IPG619)

Evidence-based recommendations on superior capsular augmentation for massive rotator cuff (shoulder) tears

Interventional procedures guidance Published July 2018

Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

Technology appraisal guidance Published June 2018 Last updated July 2018

Cenegermin for treating neurotrophic keratitis (TA532)

Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

Technology appraisal guidance Published July 2018

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)

Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

Evidence-based recommendations on niraparib (Zejula) for the possible treatment of ovarian, fallopian tube or peritoneal cancer in adults

Technology appraisal guidance Published July 2018

Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) to treat multiple sclerosis in adults

Technology appraisal guidance Published June 2018

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Technology appraisal guidance Published March 2011 Last updated June 2018

Laparoscopic ventral mesh rectopexy for internal rectal prolapse (IPG618)

Evidence-based recommendations on laparoscopic ventral mesh rectopexy for internal rectal prolapse in adults

Interventional procedures guidance Published June 2018

Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor (IPG617)

Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults

Interventional procedures guidance Published June 2018

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published June 2018

Midostaurin for untreated acute myeloid leukaemia (TA523)

Evidence-based recommendations on on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia (AML) in adults

Technology appraisal guidance Published June 2018